findmyKOL

Ruben Mesa, MD

Enriched profile

President & Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center; Vice Dean for Cancer Programs and Charles L. Spurr, MD Professor of Internal Medicine, Wake Forest University School of Medicine · Atrium Health Wake Forest Baptist Comprehensive Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Charlotte, NC · Southeast · United StatesSpecialtyHematologyFocusHematology
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2022–2026

Ruben Mesa is President & Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center; Vice Dean for Cancer Programs and Charles L. Spurr, MD Professor of Internal Medicine, Wake Forest University School of Medicine at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. OpenAlex indexes 1,282 publications with 45,977 citations (h-index 97); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 13 Oct 2026

Ruben Mesa, MD, is President & Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center. The public record shows 1,282 publications with 45,977 citations (h-index 97), centered on Hematology. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 20 companies, 1 NIH-funded awards (2022–2026).

  • Most recent indexed publication: 2026 · JCO oncology practice
  • Top research focus: Hematology
  • 15 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 20 companies

Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
MDS / MPN12 trialsPrimary Myelofibrosis11 trialsPolycythemia Vera6 trialsThrombocythemia, Essential6 trialsThrombocytosis6 trialsPolycythemia6 trialsMyeloproliferative Disorders6 trialsLeukemia (AML/ALL/CML/CLL)1 trialColorectal Cancer1 trial

Research focus

OpenAlex concept fingerprint
Hematology

Drugs & molecules

across trials, industry payments and publications
Vonjogeneric · PacritinibClinical trials1Industry payments6Publications1Jakafigeneric · RuxolitinibClinical trials—Industry payments9Publications6Ojjaarageneric · MomelotinibClinical trials—Industry payments2Publications6Inrebicgeneric · FedratinibClinical trials—Industry payments3Publications1Besremigeneric · Ropeginterferon alfa-2bClinical trials—Industry payments9Publications—Keytrudageneric · PembrolizumabClinical trials—Industry payments5Publications—PomalidomideClinical trials1Industry payments—Publications—

Works with

trial sponsors and companies reporting payments
GlaxoSmithKline, LLC.Clinical trials—Industry payments34Incyte CorporationClinical trials—Industry payments28Genentech, Inc.Clinical trials—Industry payments19Merck Sharp & Dohme LLCClinical trials—Industry payments11F. Hoffmann-La Roche AGClinical trials—Industry payments9PharmaEssentia USA CorporationClinical trials—Industry payments9Mayo ClinicClinical trials7Industry payments—Celgene CorporationClinical trials—Industry payments5Abbvie Inc.Clinical trials—Industry payments4Blueprint Medicines CorporationClinical trials—Industry payments4E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments4CTI BioPharma Corp.Clinical trials—Industry payments3Janssen Research & Development, LLCClinical trials—Industry payments3John MascarenhasClinical trials3Industry payments—MorphoSys, US Inc.Clinical trials—Industry payments3Sobi, IncClinical trials—Industry payments3Novartis Pharmaceuticals CorporationClinical trials—Industry payments2Sumitomo Pharma America, Inc.Clinical trials—Industry payments2Kyowa Kirin, Inc.Clinical trials—Industry payments1National Cancer Institute (NCI)Clinical trials1Industry payments—Novartis Pharma AGClinical trials—Industry payments1Ronald HoffmanClinical trials1Industry payments—S*BioClinical trials1Industry payments—Sierra Oncology LLC - a GSK companyClinical trials1Industry payments—Stemline Therapeutics Inc.Clinical trials—Industry payments1The University of Texas Health Science Center at San AntonioClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,282publications

Distinct works indexed by OpenAlex, matched via ORCID; 52 in PubMed.

45,977citations

Total citations across indexed works.

97h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
15clinical trials

Investigator role on registered studies.

View trials ↓
20companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2022–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Oct 2026

Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:

All 15 trial records: search, sort and filter.Explore →

Industry payments

Updated 13 Oct 2026

20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 42 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Kinase inhibitor39%
    Jakafi100%
    Part D<11 patients
    Interferon alpha18.8%
    Pegasys100%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Oct 2026

1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:

All 67 award records: search, sort and filter.Explore →

Publications

Updated 13 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 52 publications: search, sort and filter.Explore →

Online presence

Updated 13 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/ruben-mesa-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/ruben-mesa-md-0b94425

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • Other

    bloodcancerunited.org/person/ruben-mesa-md-facp

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerunited.org ↗
  • Other

    empoweredpatientradio.com/breakthrough-treatment-for-myelofibrosis-changes-care-options-with-dr-ruben-mesa-atrium-health

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →empoweredpatientradio.com ↗
  • Other

    mpnresearchfoundation.org/news/qa-with-dr-ruben-mesa

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mpnresearchfoundation.org ↗
  • Other

    aacr.org/governance/ruben-a-mesa

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
  • Other

    aamds.org/bio/ruben-mesa-md-facp

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
  • Other

    vjhemonc.com/speaker/ruben-mesa

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
  • X / Twitter

    X/Twitter handle @mpdrc attributed to Ruben A. Mesa, MD

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
  • LinkedIn

    LinkedIn: "Ruben Mesa, MD, President, Advocate Health Cancer..."

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Mayo Clinic College of Medicine and Science

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atriumhealth.org ↗
  • FACP (Fellow, American College of Physicians)
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wakehealth.edu ↗
  • Board certified

    Internal Medicine and Hematology (American Board of Internal Medicine)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atriumhealth.org ↗

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.